28/11/2004 10802583

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	4	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	5	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	6	SEP 27	STANDARDS will no longer be available on STN
NEWS	7	SEP 27	SWETSCAN will no longer be available on STN
NEWS	8	OCT 28	KOREAPAT now available on STN
NEWS	9	NOV 18	Current-awareness alerts, saved answer sets, and current search transcripts to be affected by CERAB, COMPUAB, ELCOM, and SOLIDSTATE reloads

NEWS EXPRESS	OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:09:50 ON 28 NOV 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:09:58 ON 28 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 NOV 2004 HIGHEST RN 789461-15-0
DICTIONARY FILE UPDATES: 26 NOV 2004 HIGHEST RN 789461-15-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10802583.str



chain nodes :
7 8 9 10 11 12 13 14 15
ring nodes :
1 2 3 4 5 6
chain bonds :
4-7 7-8 8-9 8-14 9-10 9-11 10-15 11-12 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
4-7 7-8 8-14 10-15 11-12
exact bonds :
8-9 9-10 9-11 11-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 17:10:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 835 TO ITERATE

100.0% PROCESSED 835 ITERATIONS 274 ANSWERS
SEARCH TIME: 00.00.01

L2 274 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.42	155.63

FILE 'CAPLUS' ENTERED AT 17:10:36 ON 28 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Nov 2004 VOL 141 ISS 23
FILE LAST UPDATED: 26 Nov 2004 (20041126/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l2 and (acetic(l)anhydride)
           253 L2
        207878 ACETIC
            22 ACETICS
        207887 ACETIC
                 (ACETIC OR ACETICS)
        192308 ANHYDRIDE
         30940 ANHYDRIDES
        202250 ANHYDRIDE
                 (ANHYDRIDE OR ANHYDRIDES)
         23809 ACETIC(L)ANHYDRIDE
L3           4 L2 AND (ACETIC(L)ANHYDRIDE)

=> d ibib abs hitstr tot
```

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:780370 CAPLUS
DOCUMENT NUMBER: 141:295750
TITLE: Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides by condensation of 2-cyano-N-(phenyl)acetamides with **acetic anhydride**
INVENTOR(S): Hachtel, Jochen; Neises, Bernd; Schwab, Wilfried; Utz, Roland; Zahn, Martin
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004186173	A1	20040923	US 2004-802583	20040317
DE 10311763	A1	20041007	DE 2003-10311763	20030318
WO 2004083165	A1	20040930	WO 2004-EP2311	20040306
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			DE 2003-10311763	A 20030318
			US 2003-490329P	P 20030725

OTHER SOURCE(S): MARPAT 141:295750
GI



AB A process is described for producing 2-cyano-3-hydroxy-N-(substituted-

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
phenyl)but-2-enamides I, in which a 2-cyano-N-(substituted-phenyl)acetamide II reacts with **acetic anhydride** in the presence of a base and at least one solvent, and the resultant I is crystd. by acidification [wherein: R1 = CF3, OCF3, SCF3, OH, NO2, halo, CH2Ph, Ph, OPh, cyano, substituted OPh (substituents = 1 or more of halo, OCF3, or OMe); R2 = alkyl, halo, H]. I are known compds. useful, e.g., for treating rheumatoid arthritis or multiple sclerosis (no data). Known processes for prepg. I give low yields and low purity. The new process provides very short reaction times, omission of addnl. purifn. steps, high yields, high purity, essentially complete reaction, and total byproduct content of <1%. For instance, II (R1 = CF3, R2 = H) in MIBK was treated with 33% NaOH soln. at 10-12°, giving a thick, creamy-colored suspension. After 10 min of stirring, the suspension was treated with Ac2O over 80 min at 7-12°, giving complete conversion to product. Further stirring, cooling to 3-5°, dropwise treatment with H2O, dropwise acidification with 37% HCl, diln. with H2O, and filtration, gave solid I (R1 = CF3, R2 = H) in 91% yield and 99.0% purity by HPLC. A variety of runs using common solvents and optional phase-transfer catalysts are reported; yields were typically lower than the cited example.

IT **108605-62-5P**, 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]but-2-enamide
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(product; improved preparation of cyanohydroxy(phenyl)butenamides by acetylation of cyano(phenyl)acetamides with **acetic anhydride**)

RN 108605-62-5 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:691069 CAPLUS
DOCUMENT NUMBER: 131:299368
TITLE: Preparation of arylpropenamides and benzopyranones as inhibitors of Burton's tyrosine kinase (BTK).
INVENTOR(S): Uckun, Fatih M.; Zheng, Yaguo; Ghosh, Sutapa
PATENT ASSIGNEE(S): Wayne Hughes Institute, USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954286	A2	19991028	WO 1999-US8556	19990419
WO 9954286	A3	20000504		
W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6303652	B1	20011016	US 1999-273191	19990319
CA 2328962	AA	19991028	CA 1999-2328962	19990419
AU 9936530	A1	19991108	AU 1999-36530	19990419
EP 1071658	A2	20010131	EP 1999-918673	19990419
EP 1071658	B1	20040616		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002512216	T2	20020423	JP 2000-544627	19990419
AT 269295	E	20040715	AT 1999-918673	19990419
US 6160010	A	20001212	US 1999-358521	19990722
US 6221900	B1	20010424	US 1999-411759	19991004
US 6294575	B1	20010925	US 2000-688426	20001016
NO 2000005224	A	20001218	NO 2000-5224	20001017
US 6365626	B1	20020402	US 2000-731989	20001207
PRIORITY APPLN. INFO.:			US 1998-82094P	P 19980417
			US 1998-97360P	P 19980821
			US 1999-273191	A 19990319
			WO 1999-US8556	W 19990419

OTHER SOURCE(S): MARPAT 131:299368
GI

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



AB Title compds. [I, II; R1 = alkyl, cycloalkyl, (substituted) Ph, amino; R2 = OH, alkoxy, alkanoyloxyaminoalkoxy, hydroxyalkoxyaminoalkanoxy, hydroxyalkanoxy; R3 = cyano, alkanoyl; R4 = H, alkyl, hydroxyalkyl, aminoalkyl; X = O, N, S; R5 = H, alkyl, CO2H; R6 = alkyl; R7, R8 undefined; with provisos], were prepared Thus, phloroglucinol in Et butyrylacetate was added to CF3SO3H under ice cooling to give 81.9% 5,7-dihydroxy-4-propylcoumarin. The latter inhibited BTK with IC50<10 μg/mL.

IT **62004-04-0P 62004-05-1P 62004-06-2P**
62004-07-3P 62004-08-4P 62004-09-5P
62004-10-8P 62004-12-0P 62004-13-1P
62004-14-2P 62004-35-7P 108605-62-5P
134319-16-7P 139442-47-0P 139442-67-4P
220512-68-5P 220512-78-7P 220512-83-4P
220512-86-7P 247095-12-1P 247095-13-2P
247095-14-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpropenamides and benzopyranones as inhibitors of Burton's tyrosine kinase)

RN 62004-04-0 CAPLUS
CN 2-Butenamide, 2-cyano-N-(3,4-dichlorophenyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RN 62004-05-1 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 62004-06-2 CAPLUS
CN 2-Butenamide, N-(2-chlorophenyl)-2-cyano-3-hydroxy- (9CI) (CA INDEX NAME)



RN 62004-07-3 CAPLUS
CN 2-Butenamide, N-(3-chlorophenyl)-2-cyano-3-hydroxy- (9CI) (CA INDEX NAME)



RN 62004-08-4 CAPLUS
CN 2-Butenamide, N-(4-chlorophenyl)-2-cyano-3-hydroxy- (9CI) (CA INDEX NAME)



RN 62004-09-5 CAPLUS
CN 2-Butenamide, 2-cyano-N-(2,4-dichlorophenyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 62004-10-8 CAPLUS
CN 2-Butenamide, 2-cyano-N-(2,5-dichlorophenyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RN 62004-12-0 CAPLUS
CN 2-Butenamide, N-(3-bromophenyl)-2-cyano-3-hydroxy- (9CI) (CA INDEX NAME)



RN 62004-13-1 CAPLUS
CN 2-Butenamide, N-(4-bromophenyl)-2-cyano-3-hydroxy- (9CI) (CA INDEX NAME)



RN 62004-14-2 CAPLUS
CN 2-Butenamide, 2-cyano-N-(4-fluorophenyl)-3-hydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 62004-35-7 CAPLUS
CN 2-Butenamide, 2-cyano-N-(2,5-dibromophenyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RN 108605-62-5 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 134319-16-7 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-phenyl- (9CI) (CA INDEX NAME)



RN 139442-47-0 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 139442-67-4 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 220512-68-5 CAPLUS
CN 2-Butenamide, 2-cyano-N-(3-fluorophenyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RN 220512-78-7 CAPLUS
CN 2-Butenamide, 2-cyano-N-(2-fluorophenyl)-3-hydroxy- (9CI) (CA INDEX NAME)



RN 220512-83-4 CAPLUS
CN 2-Butenamide, N-(2-bromophenyl)-2-cyano-3-hydroxy- (9CI) (CA INDEX NAME)

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 220512-86-7 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 247095-12-1 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-[3-(methylsulfonyl)phenyl]-, (2Z)- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.



RN 247095-13-2 CAPLUS
CN 2-Butenamide, N-[3-bromo-4-(trifluoromethoxy)phenyl]-2-cyano-3-hydroxy-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 247095-14-3 CAPLUS

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 2-Butenamide, 2-cyano-N-(2,4-dibromophenyl)-3-hydroxy- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:126254 CAPLUS
DOCUMENT NUMBER: 128:204878
TITLE: Preparation of pyrazinobenzothiazine derivatives and analogs for the treatment of inflammation and autoimmune diseases
INVENTOR(S): Kaneko, Toshihiko; Clark, Richard; Ohi, Norihito; Ozaki, Fumihiro; Kawahara, Tetsuya; Kamada, Atsushi; Okano, Kazuo; Yokohama, Hiromitsu; Muramoto, Kenzo; Arai, Tohru; Ohkuro, Masayoshi; Takenaka, Osamu; Sonoda, Jiro
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1344 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806720	A1	19980219	WO 1997-JP2787	19970808
W: AU, CA, CN, HU, JP, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2262569	AA	19980219	CA 1997-2262569	19970808
AU 9737849	A1	19980306	AU 1997-37849	19970808
ZA 9707103	A	19990208	ZA 1997-7103	19970808
EP 934941	A1	19990811	EP 1997-934750	19970808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 6518423	B1	20030211	US 1999-230852	19990405
US 2004092737	A1	20040513	US 2002-247310	20020920
PRIORITY APPLN. INFO.:			JP 1996-210344 A	19960809
			WO 1997-JP2787 W	19970808
			US 1999-230852 A3	19990405

OTHER SOURCE(S): MARPAT 128:204878
GI



AB The title compds. I [R1 to R3 are the same or different and each represents hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, etc., provided that when R1 to R3 are all optionally substituted lower alkyl groups, they do not simultaneously represent Me groups; R represents hydrogen, lower alkyl, etc.; E represents N, C, etc.; Z represents O, S, SO, SO2, etc.; and the ring G represents an optionally substituted heteroaryl ring having at least one nitrogen atom] are prepared I are useful in the treatment and prevention of

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
inflammatory immunol. diseases, autoimmune diseases, rheumatism, collagen disease, asthma, nephritis, ischemic reflow disorders, psoriasis, atopic dermatitis or rejection reactions following organ transplantation. The compd. (syn)-{3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo[3.3.1]nona-9-yl]acetic acid (II) at 10 mg/kg orally gave 65% inhibition of carrageenin-induced inflammation in rats. II in vitro showed IC50 of 2.3 μM against the expression of ICAM-1.
IT **203654-77-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazinobenzothiazine derivs. and analogs for treatment of inflammation and autoimmune diseases)
RN 203654-77-7 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-[4-[1-(1H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-1H-imidazol-4-yl]phenyl]-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:861279 CAPLUS
DOCUMENT NUMBER: 124:21813
TITLE: Treatment of platelet-derived growth factor related disorders such as cancers using inhibitors of platelet-derived growth receptor
INVENTOR(S): Hirth, Klaus Peter; Schwartz, Donna Pruess; Mann, Elaina; Shawver, Laura Kay; Keri, Gyorgy; Szekely, Istvan; Bajor, Tamas; Haimichael, Janis; Orfi, Laszlo; et al.
PATENT ASSIGNEE(S): Sugen, Inc., USA; Biosignal Ltd.; Yissum Research Development Co.; Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.; Regents of the University of California
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9519169	A2	19950720	WO 1995-US363	19950106
WO 9519169	A3	19960215		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5700823	A	19971223	US 1994-179570	19940107
CA 2180658	AA	19950720	CA 1995-2180658	19950106
CA 2180658	C	20000328		
AU 9515633	A1	19950801	AU 1995-15633	19950106
AU 690958	B2	19980507		
CN 1128496	A	19960807	CN 1995-190013	19950106
CN 1065744	B	20010516		
EP 804191	A1	19971105	EP 1995-907382	19950106
EP 804191	B1	20000517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
EP 1000617	A2	20000517	EP 1999-118607	19950106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 192925	E	20000615	AT 1995-907382	19950106
PT 804191	T	20001031	PT 1995-907382	19950106
ES 2149966	T3	20001116	ES 1995-907382	19950106
MX 9602680	A	20000630	MX 1996-2680	19960708
AU 9878832	A1	19981008	AU 1998-78832	19980806
AU 718272	B2	20000413		
GR 3034215	T3	20001229	GR 2000-401900	20000817

PRIORITY APPLN. INFO.: US 1994-179570 A 19940107

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 169120-19-8 CAPLUS
CN 2-Hexenamide, 2-cyano-3-hydroxy-5-methyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 169120-20-1 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-4,4-diphenyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

EP 1995-907382 A3 19950106

WO 1995-US363 W 19950106

OTHER SOURCE(S): MARPAT 124:21813

AB Compds. are disclosed which can inhibit platelet-derived growth factor receptor (PDGF-R) activity; preferably, such compds. also inhibit the activity of other members of the PDGF-R superfamily and are selective for members of the PDGF-R superfamily. The PDGF-R superfamily includes PDGF-R and PDGF-R-related kinases Flt and KDR. The featured compds. are active on cell cultures to reduce the activity of the PDGF-R and preferably ≥1 PDGF-R-related kinases. Using the present application as guide, other compds. able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compds. are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity. Compound A10 (leflunomide) inhibited PDGF-R autophosphoryation, PDGF-stimulated DNA synthesis, cell cycle progression, and a variety of tumor types. Preparation and biol. testing of a large number of other compds. is included.

IT **62004-16-4P**, 2-Butenamide, 2-cyano-3-hydroxy-N-(4-nitrophenyl)- **167427-78-3P 169120-19-8P 169120-20-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(platelet-derived growth factor inhibitors and their preparation for treatment of cancer and other PDGF-related disorders)

RN 62004-16-4 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 167427-78-3 CAPLUS
CN 2-Butenamide, 2-cyano-3-hydroxy-4-phenyl-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

28/11/2004 10802583

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.44	180.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.80	-2.80

STN INTERNATIONAL LOGOFF AT 17:12:53 ON 28 NOV 2004